Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Aug 22;86(9):e00114-18. doi: 10.1128/IAI.00114-18

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2018 Atcheson et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

PMC Copyright notice

FIG 5 — Assessment of vaccine efficacy using a combination of Rv21 with viral-vectored vaccines expressing P. vivax TRAP (vvTRAP) or an unrelated transgene (vvControl). (A) Table indicating the vaccination components in an 8-week prime-boost regimen, utilized to compare the efficacy against a sporozoite challenge with a combination of a P. vivax VLP (Rv21), a P. falciparum VLP (R21) with vvTRAP, or an unrelated nonmalaria antigen vvControl. (B) Survival of mice (n = 6) after a sporozoite challenge with the vaccination regimens described in panel A. (C) Titer of anti-PvCSP antibodies by Rv21 or a combination of Rv21 plus vvTRAP. (D) Ex vivo IFN-γ responses against TRAP measured by ELISpot assay. SFU, spot-forming units.